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Somatostatin has been identiﬁed as having anti-proliferative, anti-angiogenic and pro-apoptotic actions in many tumour
systems, and these effects are mediated through a family of ﬁve transmembrane G-protein coupled SRIF receptors. Ovarian
cancer is the commonest gynaecological malignancy in the UK and maintenance therapy is urgently required. Native
somatostatin expression and its receptors sst1,2,3 and 5 were studied with immunohistochemistry in 63 malignant and 35 benign
ovarian tumours of various histological types. Fifty-seven out of 63 (90%) of malignant and 26/35 (74%) benign tumours
expressed somatostatin. Receptors sst1,2,3 and 5 were expressed variably in epithelial, vascular and stromal compartments for
both benign and malignant tumours. Somatostatin was found to correlate signiﬁcantly with stromal sst1 (P=0.008), epithelial
sst1 (P50.001), stromal sst2 (P=0.019), vascular sst2 (P=0.026), epithelial sst3 (P=0.026), stromal sst5 (P=0.013) and vascular
sst5 (P=0.038). Increased expression of native somatostatin correlating with somatostatin receptors in malignant ovarian
tumours raises the possibility that either synthetic somatostatin antagonists or receptor agonists may have therapeutic
potential.
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INTRODUCTION
Ovarian cancer is the commonest of the gynaecological malignan-
cies in the western world with over 5000 new cases per annum in
the UK (Ofﬁce for National Statistics, 1998) and an overall 5-year
survival of under 30%. Current therapy relies on debulking surgery
with adjuvant chemotherapy, but relapse is common and develop-
ment of an effective maintenance treatment is needed critically.
Increased tumour vascular endothelial growth factor (VEGF)
expression is associated with a poor prognosis (Paley et al, 1997)
supporting the role of angiogenesis in the progression of this
disease, in vivo neutralisation of VEGF with antisera has been
shown to inhibit tumour growth and ascites (Olson et al, 1996).
The regulatory tetradecapeptide somatostatin (SRIF), exhibits
anti-proliferative (Buscail et al, 1994; Florio et al, 1996; Srikant,
1997), anti-angiogenic (Patel et al, 1994; Albini et al, 1999) and
pro-apoptotic actions (Sharma et al, 1996). These effects are
mediated through a family of ﬁve trans-membrane G-protein
coupled somatostatin (SRIF) receptors, which have been cloned
(Hoyer et al, 1995), activate multiple post-receptor signal transduc-
tion pathways (Patel, 1999). Synthetic SRIF analogues such as
SMS-201-995 (Sandostatin, octreotide), RC-160 (Vapreotide, octas-
tatin) and BIM-23014 (Lanreotide, somatuline) have been
developed which have varying binding afﬁnities for different recep-
tor subtypes. They have been shown to potentiate the effects of
tamoxifen in the inhibition of growth of mammary carcinomas
in nude mice (Weckbecker et al, 1994) and to control growth of
Kaposi’s sarcoma by inhibition of angiogenesis (Albini et al,
1999). Recently in a cohort of 15 serous and two mucinous ovarian
cystadenocarcinomas, 76% have been shown to demonstrate high
afﬁnity binding sites for the analogue RC-160 and RT–PCR has
shown expression of mRNA for sst1 (65%), sst2A (65%), sst3
(41%) and sst5 (24%) (Halmos et al, 2000). Therefore SRIF analo-
gues may have a role as anti-angiogenic agents in the maintenance
therapy of ovarian carcinoma. In order to explore the potential role
of native SRIF in ovarian cancer, to further determine the localisa-
tion and expression of the SRIF receptors in a variety of ovarian
neoplasms, we have examined the expression of both in a cohort
of 63 malignant and 35 benign ovarian tumours, of various histo-
logical types, using immunohistochemistry.
MATERIALS AND METHODS
Experimental subjects
Permission was obtained from the local ethics committee to access
material from the pathology archives at Hull and East Yorkshire
NHS Hospitals Trust (Hull, UK). Representative parafﬁn blocks
were taken from a cohort of 63 malignant and 35 benign ovarian
tumours of mixed histological type. The mean age of patients
studied was 57 years (range 30–84) with benign and 59 years
(range 26–85) for malignant disease. According to Federation
International of Gynaecology and Obstetrics (FIGO) classiﬁcation
for malignant ovarian disease 24 cases were stage I, seven were
stage II and 32 were stage III. The histopathology of the tumours
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The wide mix of histological subtypes is representative of the
breadth of ovarian tumours seen in clinical practice. The miscella-
neous group of malignant tumours included two granulosa cell
tumours, one carcinosarcoma, two clear cell adenocarcinomas,
one malignant carcinoid tumour, one Leydig cell tumour and eight
miscellaneous adenocarcinomas.
Immunohistochemistry
Five-micrometer thick parafﬁn sections were dewaxed and antigen
retrieval performed by microwaving at 600 W power in 10 mM
citric acid for 20 min. Serial sections were stained with SRIF and
SRIF receptor antibodies to facilitate comparisons between sections.
Somatostatin
Tissue sections were pre-incubated in 10% non-immune goat
serum (Dako Ltd, Ely, UK) for 20 min, then incubated with
primary rabbit anti-SRIF antibody (AHP533, Serotec, UK) at a
dilution of 1:40, overnight at 48C. This antibody recognises both
SRIF-14 and SRIF-28 variants. Sections were then washed with
PBS, incubated with biotinylated goat anti-rabbit IgG (Dako Ltd,
Ely, UK) at a dilution of 1:200 for 60 min, washed again with
PBS and then HRP-StrepABC (PK-6100; Vector, Burlingame, CA,
USA) was added for 45 min. Visualisation was achieved using
DAB (Sigma-Aldrich Co Ltd, Poole, Dorset, UK) as an enzyme
substrate, counterstained with haematoxylin, dehydrated and
mounted.
Somatostatin receptors
For SRIF receptor immunohistochemistry rabbit polyclonal antibo-
dies to sst1,2 and 5 were produced and provided by Dr Helboe as
previously described (Helboe et al, 1997). Rabbit polyclonal anti-
sst3 antibody was obtained from Gramsch Laboratories (Schwab-
hausen, Germany). Sections were pre-incubated in 5% non-
immune swine serum (Dako Ltd, Ely, UK) in PBS (pH 7.4) with
1% bovine serum albumin (BSA) and 0.3% Triton X-100 for
20 min at room temperature. Rabbit anti-SRIF receptor IgG was
then added diluted in PBS plus 1% BSA and 0.3% Triton X-100,
overnight at 48C. Dilutions used were 1:8000 for sst1, 1:10000
for sst2 1:5000 for sst3 and 1:7000 for sst5. Sections were washed
with PBS containing 0.25% BSA and 0.05% Tween-20, incubated
with biotinylated swine anti-rabbit IgG (E0353, Dako Ltd, Ely,
UK) at 1:500 dilution for 60 min at room temperature. Sections
were then washed in PBS with 0.05% Tween-20, incubated with
tyramide blocking buffer (supplied with the biotinylated tyramide
kit; NEL700; NEN Life Science Products, Boston, MA, USA) for
20 min, then incubated with HRP-StrepABC (PK-6100; Vector,
Burlingame, CA, USA) for 45 min. Sections were again washed
with PBS containing 0.05% Tween-20, biotinylated tyramide was
then added at 1:100 dilution for 10 min, sections were washed
again in PBS containing 0.05% Tween-20, incubated with HRP-
StrepABC for 45 min, washed again with PBS and signal visualised
with DAB prior to counterstaining, dehydrating and mounting.
Positive control experiments included normal human anterior
pituitary, which stained positively for all the SRIF receptors,
normal human pancreas, which stained positively for native SRIF.
Negative controls included adsorption studies as previously
described (Helboe et al, 1997), which abolished positive staining.
In addition omission of the primary antibody and incubation with
1% non-immune serum also abolished positive staining.
Staining was graded by intensity into negative, weak, moderate
or strong and the pattern of staining described as either focal or
uniform. The tissue compartments that stained were classiﬁed into
stromal, epithelial or vascular and the intensity of staining was
graded for each.
Statistical analysis
Results were tabulated and data analysed using the SPSS statistical
package (SPSS Professional Statistics, SPSS Inc., Illinois, USA). The
w
2 square test was used for differences in staining between benign
and malignant groups and a probability of P50.05 was considered
to be statistically signiﬁcant. The Spearman Rank test was
employed to determine correlations coefﬁcients between native
SRIF and its receptor expression.
RESULTS
SRIF expression
Fifty-seven out of 63 (90%) of malignant and 26 out of 35 (74%)
of benign tumours expressed native somatostatin (SRIF). An exam-
ple of a serous cystadenocarcinoma stained for SRIF is shown in
Figure 1. There was a trend toward more frequent expression in
the epithelium of malignant tumours (71.4%) compared to benign
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Table 1 Histopathology and number of tumours staining positive in each group for SRIF and its receptors
SRIF sst1 sst2 sst3 sst5
Histology Total E V S E V S E V S E V S E V S
Serous cystadenocarcinoma 23 17 4 8 14 12 14 8 4 15 0 0 2 10 0 4
Mucinous cystadenocarcinoma 8 7 0 5 4 2 5 3 2 4 6 0 0 5 0 3
Endometrioid adenocarcinoma 9 7 1 5 5 3 4 2 5 5 2 1 3 5 0 3
Undifferentiated carcinoma 8 6 2 3 3 1 2 2 5 3 1 0 2 5 2 5
Miscellaneous malignancy 15 8 3 9 6 5 7 4 7 9 1 1 3 8 1 6
Total n (%) 63
(100)
45
(71.4)
10
(15.9)
30
(47.6)
32
(50.8)
23
(36.5)
32
(50.8)
19
(30.2)
23
(36.5)
36
(57.1)
10
(15.9)
2
(3.2)
10
(15.9)
33
(52.4)
3
(4.8)
21
(33.3)
Cortical ﬁbroma 4 1 1 0 1 0 1 1 0 1 0 0 1 1 1 0
Indeterminate cyst 8 1 5 3 1 4 7 0 5 3 0 0 2 1 4 2
Mature teratoma 5 4 2 0 4 4 2 1 1 1 0 0 1 3 1 1
Serous cyst 2 1 0 0 1 0 0 1 2 1 1 1 2 1 2 1
Mucinous cystadenoma 10 10 1 3 10 6 7 1 2 6 6 0 2 8 3 2
Endometriotic cyst 3 0 1 2 2 1 2 0 1 2 0 0 2 1 2 0
Cystadenoﬁbroma 3 2 0 0 2 0 0 1 1 0 0 0 0 2 1 0
Total n (%) 35
(100)
19
(54.3)
10
(28.6)
8
(22.9)
21
(60.0)
15
(42.9)
19
(54.3)
5
(14.3)
12
(34.3)
14
(40.0)
7
(20.0)
1
(2.9)
10
(28.6)
17
(48.6)
14
(40.0)
6
(17.1)
E=epithelium; V=vessels; S=stroma.
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1). There was signiﬁcantly higher expression of SRIF in the vessels
of benign tumours (28.6 vs 15.9%; P=0.044) but the stromal
expression was signiﬁcantly higher in the malignant tumours
(47.6 vs 22.9%; P=0.005).
SRIF receptor expression
Epithelial staining for the SRIF receptors was uniform where
present. An endometrioid adenocarcinoma demonstrating epithelial
expression of sst5 is shown in Figure 2. Vascular staining was
largely found in the smooth muscle of the tunica media of arteries
and veins and was fairly uniform, although some endothelial stain-
ing was also seen (Figure 3). Stromal staining was more focal and
patchy (Figure 4).
Forty-eight out of 63 (76%) of malignant and 30 out of 35
(86%) benign tumours expressed sst1. There was signiﬁcantly more
frequent expression of sst1 in the epithelium (60%) of benign as
compared with malignant (50.8%) tumours (P=0.034) although
there were no differences between vascular and stromal staining
(Table 1).
There was signiﬁcantly more frequent expression of sst2 in
malignant tumours in both the epithelium (30.2 vs 14.3%;
P=0.044) and stroma (57.1 vs 40%; P=0.018) (Table 1). There was
no difference in the vascular staining. It is of interest that ﬁve out
of eight (62.5%) of undifferentiated carcinomas expressed vascular
sst2 receptors. Overall 46 out of 63 (77%) of malignant tumours
and 21 out of 35 (60%) of benign tumours expressed sst2 in at least
one of the tissue compartments.
sst3 was the least expressed of the receptors studied, with overall
only 18 out of 63 (29%) of malignant and 16 out of 35 (45%) of
benign tumours expressing it. Both six out of eight (75%) muci-
nous cystadenocarcinomas and six out of 10 (60%) mucinous
cystadenomas demonstrated epithelial sst3 (Table 1). Three
tumours demonstrated vascular expression of sst3.
Forty-ﬁve out of 63 (71%) of malignant and 25 out of 35 (71%)
of benign tumours demonstrated expression of sst5. There were no
signiﬁcant differences in epithelial or stromal expression between
benign and malignant tumours, but benign tumours expressed
signiﬁcantly higher amounts of vascular sst5 (40 vs 4.8%;
P50.001) (Table 1).
Correlation of SRIF with receptor expression
Native SRIF expression was found to correlate strongly with recep-
tor expression in the same tissue compartments in both benign and
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Figure 1 A serous cystadenocarcinoma demonstrating strong expres-
sion of SRIF by the malignant epithelium. S=Stroma, E=malignant epithe-
lium, F=ﬂuid in the cystic tumour (magniﬁcation 6200).
Figure 2 Ovarian endometrioid adenocarcinoma demonstrating uniform
membrane bound epithelial staining for sst5. E=Epithelium; S=stroma (mag-
niﬁcatoin 6200).
Figure 3 Endothelial sst1 expression in small tumour venules. V=Venule,
R=red blood cells within vessel lumen, S=stroma, E=malignant epithelium
(magniﬁcation 6400).
Figure 4 Ovarian adenocarcinoma demonstrating focal expression of
sst1 on non-malignant stromal cells. There is both membrane bound and
intracellular staining. E=Epithelium, S=stroma (magniﬁcation 6400).
SRIF and SRIF receptors in ovarian tumours
GH Hall et al
88
British Journal of Cancer (2002) 87(0), 86–90 ã 2002 Cancer Research UKmalignant tumours, as follows: stromal sst1 (P=0.008), epithelial
sst1 (P50.001), stromal sst2 (P=0.019), vascular sst2 (P=0.026),
epithelial sst3 (P=0.026), stromal sst5 (P=0.013) and vascular sst5
(P=0.038).
DISCUSSION
The results form this large cohort of benign and malignant ovarian
tumours show that both express high levels of native SRIF as well
as the receptors sst1,2,3 and 5. We aimed speciﬁcally to determine
whether malignant epithelium and blood vessels, as well as
supporting stromal cells, expressed SRIF or its receptors. The
presence of SRIF receptors on malignant epithelium is of great rele-
vance to the potential use of SRIF analogues as chemotherapeutic
agents, as is the presence of receptors on blood vessels for the
potential use of SRIF analogues as anti-angiogenic therapy.
The expression of native SRIF by epithelial ovarian tumours is
intriguing and its relationship with its receptor expression has
not been well documented. SRIF occurs naturally in two forms, a
14 amino acid form (SRIF-14) and a 28 amino acid form (SRIF-
28). Both are biologically active and bind to receptors. SRIF has
previously been shown to be expressed by neuroendocrine ovarian
carcinoid tumours (Sporrong et al, 1982). These tumours are
exceptionally rare and demonstrate a different biological and clin-
ical behaviour to the common epithelial ovarian tumours. SRIF
mRNA production has been demonstrated in 14 out of 30 ovarian
adenocarcinomas and two out of three borderline tumours (Reubi
et al, 1993). In that study translation of mRNA was not conﬁrmed
by examining peptide expression and receptor autoradiography
demonstrated SRIF receptors in only two of the 33 ovarian
tumours. SRIF production has been demonstrated in the normal
ovaries of many species, but in the human ovary it has only been
demonstrated in follicular ﬂuid to date (Holst et al, 1994). In this
study we have examined the expression of both forms of SRIF in
ovarian neoplasms, but have not examined expression in normal
ovarian tissue.
As the actions of SRIF are inhibitory in most biological systems,
it might have been expected that SRIF be expressed in benign
lesions and this expression lost in malignancy. This was not the
case, however, and raises further questions as to the role of SRIF
in the pathophysiology of ovarian disease. Epithelial expression
of SRIF was much greater than vascular or stromal, most of the
SRIF staining was in the malignant cells themselves. The high levels
of SRIF in ovarian malignancy may even suggest a stimulatory role
in tumour growth through an autocrine positive feedback loop,
perhaps involving up-regulation of receptors. This would not be
unique, as SRIF-14 has been reported to stimulate tumour growth
in the SHP-1 deﬁcient pancreatic cell line MIA PaCa-2 whilst it
inhibits growth in the SHP-1 positive PANC-1 cell line (Douziech
et al, 1999). Further work is required to investigate the role of
SHP-1 in ovarian cancer and to explore the actions of SRIF on
the dynamics of tumour cells.
This study conﬁrms that most ovarian tumours express SRIF
receptors, but shows that there are differences in expression pattern
between benign and malignant groups and between histological
types. The malignant epithelium of ovarian tumours expresses high
levels of sst1, 2 and 5 as well as SRIF itself. This suggests that SRIF
may have a role in the progression of ovarian cancer. sst3 was only
expressed in low amounts, as it is the receptor subtype thought to
be most involved in stimulating apoptosis (Sharma et al, 1996), its
low expression may be a signiﬁcant factor in tumour progression.
The strong correlations seen between SRIF and its receptors suggest
that SRIF can cause up-regulation of its own receptors and be
involved in auto-regulation of tumour growth. Of particular note
is that vessels within even the most undifferentiated anaplastic
tumours still express SRIF receptors and thus may be potential
targets for therapy with the anti-angiogenic synthetic SRIF analo-
gues.
An early report of SRIF receptor expression in ovarian tumours
using in vitro receptor autoradiography found only 3/57 positive
tumours (Reubi et al, 1991). A recent rapid communication of
15 serous and two mucinous cystadenocarcinomas, used radiola-
belled RC-160 binding assays, speciﬁc for sst2 and 5, RT–PCR, to
demonstrate expression of SRIF receptors in malignant ovarian
tumours (Halmos et al, 2000). Whilst conﬁrming that these two
types of tumour expressed SRIF receptors, this methodology did
not allow the anatomical localisation of receptor expression with
respect to the malignant cells or surrounding normal stromal
tissues. This is important to our understanding of the pathophy-
siology of the disease and how speciﬁc receptor targeting may act
therapeutically.
SRIF analogues may exert their effects through both direct and
indirect mechanisms (Pollak and Schally, 1998). Thus, even if
tumour cells themselves do not express SRIF receptors, analogues
may still inhibit tumour growth by indirect actions on other
cells. One example of this is prevention of proliferation of an
SRIF receptor-negative chondrosarcoma by the analogue SMS-
201-995 via inhibition of growth hormone, insulin like growth
factor-1 (IGF1) and insulin (Reubi, 1985). In Kaposi’s sarcoma
models, both in vitro and in vivo, SRIF has been shown to be
a pure anti-angiogenic agent in its own right, inhibiting growth
of SRIF receptor negative tumours (Albini et al, 1999). The stro-
mal expression of SRIF and its receptors is important in many
body systems, and is likely to be so in ovarian cancer too.
The subtle interactions between malignant cells and their
supporting stroma are poorly understood. Tumour associated
macrophages have been reported in both benign and malignant
ovarian tumours (Orre and Rogers, 1999), have been shown to
have positive inﬂuence on tumour vascularisation. Some of the
stromal cells expressing SRIF receptors (e.g. Figure 4) may be
tumour-associated macrophages, it is possible that SRIF analo-
gues might effect an action through this route. The
demonstration of expression of SRIF receptors on stromal cells
within ovarian tumours means that SRIF analogues could poten-
tially alter tumour growth indirectly, by inhibiting stromal cell
production of growth factors.
SRIF receptors have been described in both normal human
blood vessels (Curtis et al, 2000) and veins surrounding human
cancers (Reubi et al, 1994, 1996). IGF-1 stimulates growth of
new blood vessels in experimental systems (Nakao-Hayashi et al,
1992) and potentially SRIF analogues may inhibit tumour growth
indirectly by decreasing IGF-1 production. As SRIF receptors are
expressed on peritumoral vessels they may act directly to inhibit
angiogenesis or affect tumour biology by causing vasoconstriction
and thus decreasing tumour blood ﬂow (Reubi et al, 1996). The
post-receptor signal transduction pathways in octreotide-induced
inhibition of angiogenesis have been studied in the chick embryo
system and have been shown to depend on G proteins, calcium
and cyclic adenosine monophosphate (Patel et al, 1994). Our study
has shown high-level expression of sst1 and sst2 in the vessels of
both benign and malignant ovarian tumours, so there is potential
for SRIF analogues to inhibit angiogenesis by both direct and indir-
ect mechanisms. Vascular sst5 was expressed in 40% of benign and
only 4.8% of malignant lesions, which may suggest that either the
loss of sst5, which is postulated to have tumour suppressor actions,
by benign vessels leads to the more rapid angiogenesis associated
with malignancy, or that the increased production of SRIF by
malignant lesions may lead to down-regulation of the vascular
sst5 receptors.
Studies are already underway to look at the potential role of
SRIF analogues in therapy of other solid tumours. SRIF analogues
have been shown to be beneﬁcial in a rat model where they
potentiate the effects of tamoxifen (Weckbecker et al, 1994) and
clinical trials in advanced breast cancer are underway (Bontenbal
et al, 1998; O’Byrne et al, 1999). In ovarian cancer models the
anti-angiogenic agents endostatin and angiostatin have been shown
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2000). There is also evidence that the SRIF analogue RC-160 can
inhibit growth of the ovarian cell line OV-1063 (Yano et al,
2000), but it cannot be extrapolated that this is true of all ovarian
tumours in vivo. This gives hope that SRIF analogues may also
prove efﬁcacious by a combination of both the direct and indirect
mechanisms. The cytotoxic SRIF analogue AN-238 has been shown
to inhibit proliferation of SRIF receptor positive cells from the
UCI-107 ovarian carcinoma cell line in vitro (Plonowski et al,
2001). Our study provides further rationale for exploring the
potential therapeutic use of cytotoxic radionulide SRIF analogues
in clinical trials of ovarian cancer.
We have shown the expression of SRIF and its receptors in both
the epithelial and vascular compartments of benign and malignant
epithelial ovarian tumours and have also noted signiﬁcant stromal
expression. It is likely that sst1, 2 and 5 will be more clinically
important targets than sst3 for analogue mediated therapy. The role
of SRIF and its receptors in the pathophysiology of ovarian disease
requires further investigation as it may have either stimulatory or
inhibitory actions.
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